Case Reports in Rheumatology
Volume 2019 (2019), Article ID 6173869, 4 pages
https://doi.org/10.1155/2019/6173869

Case Report

Destructive Upper Airway Disease from Eosinophilic Granulomatosis with Polyangiitis (EGPA): The Very First Case

Biplab Saha,¹ Aditi Saha,² Fernanda Cordeiro-Rudnisky,³ Boris Shkolnik,¹ and Scott Beegle¹

¹Division of Pulmonary and Critical Care Medicine, Albany Medical Center, Albany, NY, USA
²Department of Medicine, Saint Barnabas Medical Center, Livingston, NJ, USA
³Department of Pathology, Albany Medical Center, Albany, NY, USA

Correspondence should be addressed to Biplab Saha; spanophiliac@yahoo.com

Received 16 March 2019; Accepted 5 May 2019; Published 23 May 2019

Academic Editor: Mehmet Soy

Copyright © 2019 Biplab Saha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystem vasculitic disorder that predominantly affects medium- and small-sized blood vessels. EGPA belongs to a group of vasculitides known as anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV). Upper airway involvement is seen in all ANCA-associated vasculitides, but destructive upper airway disease has never been reported in patients with EGPA. We report the first case of erosive chondritis and saddle nose deformity in a 50-year-old patient suffering from EGPA.

1. Introduction

Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a multisystem vasculitic disorder that predominantly affects small-sized blood vessels. EGPA belongs to a group of vasculitides known as anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV). The other members of this category include granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis and microscopic polyangiitis (MPA). Although these diseases share many common features, EGPA is unique in its presentation and usually follows a stepwise disease progression characterized by a prodromal period followed by an eosinophilic and vasculitic phases [1]. Upper airway involvement is seen in all ANCA-associated vasculitides, but destructive upper airway disease has never been reported in patients with EGPA. Here, we present the first case of saddle nose deformity due to erosive chondritis in a patient suffering from EGPA.

2. Case Presentation

A 50-year-old Caucasian female with a history of difficult-to-control asthma since 1994 and chronic rhinitis presented to the hospital with severe jaw and ear pain in late February of 2009. She had been suffering from intermittent pain for a few months and underwent bilateral myringotomy tube placement about a month prior for recurrent otitis media with some benefit. The pain was distributed over the rami of the mandible bilaterally with radiation to her ears. She denied any fever, night sweats, weight loss, purulent nasal discharge, odynophagia, dysphagia, or shortness of breath. No significant history of travel or sick contact including contact to TB patients. The patient was a past smoker with 15 pack year history of smoking.

Vital signs on admission showed a BP of 101/63 mm·Hg, pulse of 105 beats/minute, temperature of 97.9 F, respiratory rate of 18 breaths/min, and SPO₂ of 96% on room air. Physical examination revealed a patient in moderate distress. Bilateral tenderness was elicited while palpating the mandibular rami. The myringotomy tubes were intact without and significant drainage. The nasal mucosa appeared normal without any evidence of erythema, epistaxis, or discharge. The rest of the physical examination was unremarkable. The laboratory data are shown in Table 1.

Table 1: Admission laboratory values.

Laboratory test
Result
Normal value

WBC
20.4
4.1–9.3 × 10³/μL

Neutrophil (%)
70
41–67

Lymphocyte (%)
11
28–42

Eosinophil (%)
12
0–5

Absolute eosinophil
2492
50–500/μL

Hemoglobin
9.7
11–14.7 gm/dL

Hematocrit
28.5
33–44

Platelet
589
130–350 × 10³/μL

Electrolytes
Within normal range
—

BUN
5
7–21 mg/dL

Creatinine
0.7
0.7–1.2 mg/dL

Albumin
1.8
3.5–5.2 gm/dL

Total protein
6.3
6–8 gm/dL

Total bilirubin
0.9
0.1–1.2 mg/dL

ALT
67
5–60 IU/L

AST
81
5–45 IU/L

Alkaline phosphatase
179
30–115 IU/L

CRP
187
<8 mg/dL

ESR
115
0–25 mm/hour

Urinalysis showed trace proteinuria and no RBC cast. Electrocardiogram and a chest X-ray were normal. She underwent a CT scan of her neck with contrast which was unremarkable except left maxillary sinus thickening. However, the apical part of the lungs showed multiple nodules bilaterally. A dedicated high-resolution CT scan of the chest revealed multiple bilateral nodules, 5–11 mm in diameter. The largest nodule was noted in the lingula that measured 11 × 9 mm. There was also evidence of pericarditis and small pericardial effusion. Given her long standing history of uncontrolled asthma, upper airway symptoms, eosinophilia, and multiple pulmonary nodules, a clinical diagnosis of EGPA was made and the patient underwent an extensive rheumatologic workup which is shown in Table 2.

Table 2: Rheumatologic workup.

Laboratory test
Result
Normal value

ANA
Negative
<320

Cytoplasmic ANCA
<20
<20

Perinuclear ANCA
40
<20

Atypical ANCA
<20
<20

Anti-myeloperoxidase antibody
49.1 H
<20

Anti-proteinase 3 antibody
2.3
0–3.5

Rheumatoid factor
142 H
<20

Anti-CCP
<15
<20

Anti-cardiolipin IgG, IgA, IgM
<15
<20

Beta-2 glycoprotein IgG, IgA, IgM
<9
<20

CH50
55
22–60

C3
147
70–163

C4
23.3
12–51

Anti-SSA
10
0–99

Anti-SSB
9
0–99

Anti-Jo
<0.2
0.0–0.9

Angiotensin converting enzyme (ACE)
20
12–68

Hepatitis panel
Negative
Negative

Anti-streptolysin O
44
<125

The patient underwent an open lung biopsy of the lingular nodule as well as a pericardial biopsy. The histopathology was consistent with necrotizing granulomatous vasculitis with extravascular eosinophilic infiltrate. The histopathology slides are shown in Figures 1 and 2. The diagnosis of EGPA was confirmed.

(a)

(b)

Figure 1: (a) Large pulmonary arterial branch with fibrinoid necrosis, granulomatous inflammation, and eosinophil-rich infiltrate (H&E stain, 40x). (b) Higher power demonstrating eosinophil-rich inflammatory infiltrate associated with fibrinoid necrosis (H&E stain, 100x).

Figure 2: Small pericardial artery with vasculitis including numerous eosinophils (H&E stain, 200x).

The patient was started on high-dose prednisone and azathioprine in March 2009. She initially did well, but in August 2009 the patient was admitted to the hospital with pulmonary edema secondary to heart failure with reduced ejection fraction (HFrEF). The echocardiogram showed an EF of 25–30% with biventricular dilatation and global hypokinesis. No wall motion abnormality was identified. Cardiac catheterization was negative for coronary artery disease. No endomyocardial biopsy was performed. Given the high incidence of cardiac involvement in EGPA and a negative coronary angiogram, the myocardial dysfunction was thought to be secondary to EGPA and she was started on IV cyclophosphamide. Over the course of next 6 months, the patient completed 6 cycles of IV cyclophosphamide and started on mycophenolate. Steroid taper was continued. Her EF recovered completely, but she suffered from multiple vertebral body compression fractures and developed cushingoid appearance secondary to chronic steroid therapy. Between September 2009 and July 2011, she suffered from 2 episodes of sinusitis which was treated with short course of antibiotic. Her disease remained well controlled with normal inflammatory markers.

During an office visit in July 2011, the patient was noted to have depressed nasal ridge (Figure 3). Physical examination showed nasal mucosal erythema. The patient underwent reconstruction of her nasal bridge in July 2013. Since 2011, the patient has been managed with mycophenolate without any incidence of exacerbation and is doing well currently.

Figure 3: Saddle nose deformity.

3. Discussion

Our case represents the first case of saddle nose deformity secondary to EGPA that was confirmed by lung and pericardial biopsy.

EGPA is one of the AAV syndromes that predominantly affect medium- to small-sized vessels. Although EGPA can involve any organ system, upper airway, peripheral nerves, skin, and lungs are most commonly involved [2]. Ear, nose, and throat (ENT) involvement is manifested by allergic rhinitis, recurrent sinusitis, otitis media, nasal obstruction, and nasal polyposis [3]. Clinically, EGPA is characterized by long-standing history of rhinosinusitis, difficult-to-control asthma, and peripheral eosinophilia [4]. Histopathology in the vasculitic phase of the disease reveals eosinophilic infiltration of the vessel walls and necrotizing eosinophilic granuloma in extravascular tissue [5].

Destructive upper airway disease, such as saddle nose deformity (SND), is a well-known manifestation of AAV syndromes, especially with GPA [6]. Other causes of SND include relapsing polychondritis (RP), granulomatous infection, lymphomatoid granulomatosis, lymphoma, carcinoma, and trauma. Although significant ENT symptoms can be present in any of the AAV and contribute to patients suffering, destructive upper airway disease is a classic manifestation of GPA [6]. ENT involvement is seen in up to 90% of patients with GPA during the course of their disease [7]. Nasal septal perforation, mucosal ulceration, and collapse of the nasal bridge leading to SND are well-known complications of GPA [7]. The diagnosis of GPA is often delayed in patients with nonerosive ENT symptoms as they are initially mistakenly attributed to allergic etiology before an extensive workup is undertaken.

ENT involvement is common with EGPA, and paranasal sinus abnormalities have been included as one of the diagnostic criteria proposed by American College of Rheumatology [8, 9]. In a large observational French study that retrospectively reviewed 383 patients with EGPA diagnosed between 1957 and 2009, 48% of patients were found to have ENT involvement on presentation. The most common symptoms included rhinitis, nonerosive sinusitis, and nasal polyposis. Destructive upper airway manifestations, such as SND or septal perforation, were not present in any of the patients. 60% of patients with ENT involvement were found to be ANCA positive [2]. According to five-factor scoring (FFS) system, presence of ENT symptoms is considered to convey better prognosis [10].

The presence of SND in our patient is an intriguing clinical manifestation that has never been reported in patients with EGPA. Her other symptoms including difficult-to-control asthma over many years, chronic rhinosinusitis, otitis media, eosinophilia, and pulmonary infiltrate are consistent with typical progression of EGPA that was eventually confirmed by a lung biopsy. Why she suffered from erosive ENT disease is unknown.

Historically, GPA has been associated with presence of cytoplasmic-ANCA (C-ANCA), while MPA and EGPA have been characterized by perinuclear-ANCA (P-ANCA) positivity on immunofluorescence staining of ethanol-fixed human leukocytes [7]. With the advent of enzyme-linked immunosorbent assay (ELISA), most C and P-ANCA autoantibodies have been identified as anti-proteinase 3 (PR3) and anti-myeloperoxidase (MPO) antibodies, respectively. Thus, GPA is typically positive for PR3-ANCA, whereas MPA and EGPA are positive for MPO-ANCA. However, some patients with GPA and a positive C-ANCA have anti-MPO antibody and patients with EGPA or MPA are positive for P-ANCA with anti-PR3 antibody. The rate of ANCA positivity varies based on the type of AAV. In EGPA, the ANCA is positive in about 50% of patients [7]. The severity of AAV has been proposed to be related to the type of autoantibody rather than the individual vasculitic syndrome [11]. In general, presence of PR3-ANCA is considered to be associated with worse disease severity and more relapse [11].

Our patient suffered from severe EGPA with cardiac, lung, and upper airway involvement. She was treated initially with glucocorticoid and azathioprine. Subsequently, she required IV cyclophosphamide therapy for worsening disease. It is possible that the SND was a manifestation of severe systemic inflammation and developed slowly over a 2-year period, although the inflammatory markers were normal when SND was first observed. Even in patients with severe disease, SND has not been reported in the past. Presence of both MPO and PR3-ANCA together has been reported in patients with anti-GBM antibody disease [12] and users of cocaine contaminated with levamisole [13]. The patient was checked for PR3-ANCA positivity many times over the years, but there was no evidence for overlap syndrome. The other possibility would be lack of reporting due to attribution of SND to other causes.

4. Conclusion

Erosive upper airway disease from EGPA is unheard of and has never been reported. The knowledge regarding the presence of autoantibodies in AAV and their roles is disease causation, and manifestation is continuously evolving. We are reporting the first case of SND from EGPA with the hope to enrich the medical literature and encourage further research into identification of different disease phenotypes and move forward towards individualized management of these complicated life-threatening diseases.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

R. A. Sinico and P. Bottero, “Churg–Strauss angiitis,” Best Practice & Research Clinical Rheumatology, vol. 23, no. 3, pp. 355–366, 2009.

C. Comarmond, C. Pagnoux, M. Khellaf et al., “Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort,” Arthritis & Rheumatism, vol. 65, no. 1, pp. 270–281, 2013.

A. Bacciu, C. Buzio, D. Giordano et al., “Nasal polyposis in Churg–Strauss syndrome,” The Laryngoscope, vol. 118, no. 2, pp. 325–329, 2008.

C. Pagnoux and L. Guillevin, “Churg–Strauss syndrome: evidence for disease subtypes?” Current Opinion in Rheumatology, vol. 22, no. 1, pp. 21–28, 2010.

L. Guillevin, P. Cohen, M. Gayraud, F. Lhote, B. Jarrousse, and P. Casassus, “Churg–strauss syndrome clinical study and long-term follow-up of 96 patients,” Medicine, vol. 78, no. 1, pp. 26–37, 1999.

L. T. Tan, I. Davagnanam, H. Isa et al., “Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement,” Ophthalmology, vol. 121, no. 6, pp. 1304–1309, 2014.

P. Seo and J. H. Stone, “The antineutrophil cytoplasmic antibody-associated vasculitides,” American Journal of Medicine, vol. 117, no. 1, pp. 39–50, 2004.

A. Bacciu, S. Bacciu, G. Mercante et al., “Ear, nose and throat manifestations of Churg–Strauss syndrome,” Acta Oto-Laryngologica, vol. 126, no. 5, pp. 503–509, 2006.

A. T. Masi, G. G. Hunder, J. T Lie et al., “The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis),” Arthritis and Rheumatism, vol. 33, no. 8, pp. 1094–1100, 1990.

L. Guillevin, C. Pagnoux, R. Seror, A. Mahr, L. Mouthon, and P. L. Toumelin, “The five-factor score revisited,” Medicine, vol. 90, no. 1, pp. 19–27, 2011.

M. Hilhorst, P. van Paassen, and J. W. C. Tervaert, “Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis,” Journal of the American Society of Nephrology, vol. 26, no. 10, pp. 2314–2327, 2015.

J. B. Levy, T. Hammad, A. Coulthart, T. Dougan, and C. D. Pusey, “Clinical features and outcome of patients with both ANCA and anti-GBM antibodies,” Kidney International, vol. 66, no. 4, pp. 1535–1540, 2004.

M. M. McGrath, T. Isakova, H. G. Rennke, A. M. Mottola, K. A. Laliberte, and J. L. Niles, “Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 12, pp. 2799–2805, 2011.